首页> 美国卫生研究院文献>The Journal of Venomous Animals and Toxins Including Tropical Diseases >Cytotoxic and pro-apoptotic action of MjTX-I a phospholipase A2 isolated from Bothrops moojeni snake venom towards leukemic cells
【2h】

Cytotoxic and pro-apoptotic action of MjTX-I a phospholipase A2 isolated from Bothrops moojeni snake venom towards leukemic cells

机译:MjTX-1(一种从Bothrops moojeni蛇毒中分离出的磷脂酶A2)对白血病细胞的细胞毒性和促凋亡作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundChronic myeloid leukemia (CML) is a BCR-ABL1+ myeloproliferative neoplasm marked by increased myeloproliferation and presence of leukemic cells resistant to apoptosis. The current first-line therapy for CML is administration of the tyrosine kinase inhibitors imatinib mesylate, dasatinib or nilotinib. Although effective to treat CML, some patients have become resistant to this therapy, leading to disease progression and death. Thus, the discovery of new compounds to improve CML therapy is still challenging. Here we addressed whether MjTX-I, a phospholipase A2 isolated from Bothrops moojeni snake venom, affects the viability of imatinib mesylate-resistant Bcr-Abl+ cell lines.
机译:背景慢性粒细胞白血病(CML)是一种BCR-ABL1 + 骨髓增生性肿瘤,其特征在于骨髓增生增加和抗凋亡的白血病细胞的存在。当前CML的一线治疗是给予酪氨酸激酶抑制剂甲磺酸伊马替尼,达沙替尼或尼洛替尼。尽管有效治疗CML,但一些患者已对该疗法产生抗药性,导致疾病进展和死亡。因此,发现改善CML治疗的新化合物仍然具有挑战性。在这里,我们探讨了MjTX-1(一种从Bothrops moojeni蛇毒中分离的磷脂酶A2)是否影响耐甲磺酸伊马替尼的Bcr-Abl + 细胞系的生存能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号